A pharmacokinetic sub-study of the phase 3 TIGeR-PaC trial found that intra-arterial gemcitabine delivered via RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) platform produced significantly lower systemic drug exposure than standard IV administration.
The analysis found that approximately half of the intra-arterial dose was extracted at the tumor site before reaching systemic circulation, suggesting the potential to reduce systemic toxicities while maintaining local efficacy.
RenovoRx today announced its financial results for the second quarter ended June 30, 2026, and provided shareholders with a business update highlighting continued commercial momentum and clinical progress.
RenovoRx is pleased to announce completion of enrollment in the Company’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer (LAPC).
RenovoRx today announced the first commercial clinical use of RenovoCath for drug-delivery in the treatment of a patient with sarcoma at the CARTI Cancer Center Little Rock (“CARTI”).
RenovoRx today announced it will participate in a JonesTrading webinar with oncology key opinion leaders (KOLs) and Shaun Bagai, Chief Executive Officer of RenovoRx, on August 13, 2026 at 1:30 p.m. ET.